All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Multiple Myeloma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

COMy 22

Share:

Jun 29, 2022

X post image

9 Nov 2022

Have you seen this?
#COMy22 | 🎥 The MM Hub was pleased to speak to @rajshekharucms, Herbert Irving Comprehensive Cancer Center. We asked, What are the initial results of antibody–drug conjugate (ADC)-based combinations?
Watch the video here 👇
https://t.co/d6yKPUe8ww

X post image

25 Oct 2022

Have you seen this?
#COMy22 | 🎥 The MM Hub was pleased to speak to @IreneGhobrial, @DanaFarber. We asked, What have we learnt about monoclonal gammopathy of undetermined significance (MGUS) prevalence and clinical implications?
#myeloma #mmsm
https://t.co/5SgDHBJ5RW

X post image

8 Oct 2022

🎥Weekend Rewatch
During the #COMy22, the Multiple Myeloma Hub was pleased to speak to @H_Einsele, Hermann Einsele, Julius-Maximilians-Universität Würzburg. We asked, How do you manage bridging therapies prior to CAR T cells in multiple myeloma? https://t.co/9CklcTJHkw #MMsm

X post image

1 Oct 2022

🎥 Weekend watch!
During #COMy22, the MM Hub was pleased to speak to María-Victoria Mateos, University Hospital of Salamanca. We asked, What are the current and future strategies for maintenance therapy after autologous transplant?

https://t.co/0eIrqHXtW9

X post image

1 Aug 2022

At #COMy22, Sonja Zweegman discussed how ultra-frail patients with multiple #myeloma are at higher risk of treatment discontinuation and adverse outcomes and how crucial it is to identify them in the clinic accurately.
Read a summary here👇
#mmsm #gerionc
https://t.co/DBYkB32CpN

X post image

5 Jul 2022

🎥 During the #COMy22 , the MM Hub was pleased to speak to @rajshekharucms, Herbert Irving Comprehensive Cancer Center. We asked, What are the initial results of antibody–drug conjugate (ADC)-based combinations❓
Watch the video here 👇
https://t.co/d6yKPUdAGY

X post image

21 Jun 2022

🎥 During the #COMy22, the MM Hub was pleased to speak to @IreneGhobrial, @DanaFarber. We asked, What have we learnt about monoclonal gammopathy of undetermined significance (MGUS) prevalence and clinical implications❓
#myeloma #mmsm
https://t.co/5SgDHBJ5RW

X post image

17 Jun 2022

🎥 During the #COMy22, the Multiple Myeloma Hub was pleased to speak to @H_Einsele, Julius-Maximilians-Universität Würzburg. We asked, How do you manage bridging therapies prior to CAR T cells in multiple myeloma❓

https://t.co/9CklcTJ9uY

X post image

15 Jun 2022

🎥 During #COMy22, the MM Hub was pleased to speak to @AjaiChari, @IcahnMountSinai. We asked, Which targets are being explored in myeloma with bispecific antibodies❓

https://t.co/1kYYUfEVDy

X post image

13 Jun 2022

🎥 During #COMy22, the MM Hub was pleased to speak to María-Victoria Mateos, University Hospital of Salamanca. We asked, What are the current and future strategies for maintenance therapy after autologous transplant❓

https://t.co/0eIrqHXtW9

X post image

16 May 2022

RT @healthhashtags: Top Influencers of #COMy22: @COMyCongress @MM_Hub @profghjackson @VJHemOnc @Mohty_EBMT @DrRakeshPopat More 📊 https://t.…

X post image

15 May 2022

CONGRESS | #COMy22 | Nathan Sweeney et al presented their poster on use of high-dose melphalan (HDM) with ASCT. The results found no significant difference in increase of mutations post treatment, and suggests HDM does not increase MM risk level, compared to chemotherapy alone.🩺

X post image

15 May 2022

CONGRESS | #COMy22 | There is an improvement in depth of response when additional therapy is added
> Different approaches to measure MRD will be important

#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Morgan described therapy resistance as a marker of risk, and the importance of biallelic inactivation of tumor suppression genes at relapse
#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Morgan considered the evolution of MM and a Darwinian view of treatment, including analysing patterns of clonal composition at relapse, with a small number of pts demonstrating new changes from baseline, which is typical of non-CR #mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Gareth Morgan, @nyulangone, outlined how to assess risk status during therapy, highlighting the importance of functional risk assessment, prognostic importance of biallelic inactivation of TP53, and amplification of chromosome 1

#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Dimopoulos described the outcomes for pts who are refractory to lenalidomide, highlighting improved PFS and OS with PomVd vs Vd
> The CANDOR study showed benefit of dara-Kd for PFS across prior lines of therapy with Len

#mmsm #myeloma

X post image

15 May 2022

#COMy22 | Isa-Kd also showed promising results for achieving MRD negativity in pts who received ≥ 3 prior lines of lenalidomide

#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Dimopoulos outlined treatment options for patients who are lenalidomide naïve or sensitive, and how to define lenalidomide refractoriness

#mmsm #myeloma

X post image

15 May 2022

#COMy22 | Meletios Dimopoulos , @uoaofficial, discussed therapy for MM at first relapse, firstly highlighting that MRD negativity in RRM is associated with better OS and PFS
The choice of second line therapy will depend on the type of treatment pt received in front line
#mmsm

X post image

15 May 2022

CONGRESS | #COMy22 | Zweegman provided insight into the patient preference and the value of toxicity over PFS
#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | In the HOVON for trial Ixa-Dara-dex, 80% of pts had other frailty factors in combination or irrespective of age
Pts defined as frail based on age alone had a higher median PFS
#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Sonja Zweegman, @amsterdamumc, described treatment of the ultra-frail patients, highlighting a need for better refinement of frailty in clinical trials
#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Most people with MGUS die of another cause before any progression event to MM occurs, so its important to screen pts with MGUS for other diseases
#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Any unexplained symptoms should require a bone marrow biopsy and bone survey
A follow up of 6 months is given dependent of risk stratification, with low-risk pts not requiring a follow up
#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Rajkumar defined who should undergo MGUS testing, highlighting increased prevalence of MGUS in first degree relatives and racial disparities
#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Revised IMWG shows that MGUS requires no myeloma defining events, and MGUS can be defined into three subtypes
#mmsm

X post image

15 May 2022

CONGRESS | #COMy22 | @VincentRK, @mayoclinic, outlined diagnosis, risk stratification and management of MGUS
#mmsm #myeloma

X post image

15 May 2022

#COMy22 | Niels van de Donk, @amsterdamumc, presented the first results from cohort B of the CARTITUDE-2 study with cilta-cel, for pts with early relapse after initial therapy that included a PI and IMiD

ORR was 95%, 79% of pts achieved ≥CR & 90% achieved ≥VGPR
#mmsm

X post image

15 May 2022

#COMy22 | CRS occurred in 84% of pts (one grade 4) & ICANS (grade 1) occurred in 1 pt
One pt experienced movement and neurocognitive TEAEs (grade 3) on Day 38 post cilta-cel infusion

#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | @szusmani, @MSKCancerCenter, presented preliminary findings from the DREAMM-9 study, investigating belamaf plus VRd in pts with transplant-ineligible NDMM

> No new safety signals were observed, and early data showed high response rates

#mmsm #myeloma

X post image

15 May 2022

#COMy22 | Effectiveness of IRd is consistent with its efficacy in TOURMALINEMM1 (median PFS, 19.9 vs 20.6 months), with no new safety signals

Findings suggest a treatment benefit with IRd in earlier vs later lines in both non frail and frail pts

#mmsm #myeloma

X post image

15 May 2022

CONGRESS | #COMy22 | Xavier Leleu, @UnivPoitiers, presented data from the INSURE study, a global pooled analysis evaluating the effectiveness of IRd for RRMM in routine clinical practice

#mmsm #myeloma

X post image

15 May 2022

📰 It's the final day of #COMy22!

The MM Hub will be covering:
Session 15: Abstract communications
Session 16: Special lectures

Follow us on twitter (@mm_hub) for the latest updates from today! 🗞️

#mmsm @COMyCongress

X post image

14 May 2022

CONGRESS | #COMy22 | Aikaterini Panopoulou et al. presented their poster, showing Double-Hit chromosomal aberrations leads to adverse outcomes in pts with NDMM who are undergoing ASCT. Pts with Double-Hit had significantly shorter median PFS. 🩺 #MMsm

X post image

14 May 2022

CONGRESS | #COMy22 | Paul Richardson, @Danafarber, discusses the use of immune therapies in the relapse setting

#mmsm #myeloma

X post image

14 May 2022

CONGRESS | #COMy22 | @H_Einsele, @Uni_WUE, discussed integrating immune therapies and autologous transplantation, including arguments for moving CAR-T and bispecific antibodies to earlier lines of therapy

#mmsm #myeloma

X post image

14 May 2022

CONGRESS | #COMy22 | Salomon Manier,
@CHU_Lille, discussed the clinical management of cytokine release syndrome (CRS) and neurotoxicity

#mmsm #myeloma

X post image

14 May 2022

#COMy22 | Cons continued...

> Meta-analysis has shown that CAR-T therapy is associated with high relapse rates
> Strategies to enhance durability of CAR-T response are needed

#mmsm #myeloma

X post image

14 May 2022

#COMy22 | Cons continued...

> Improvement in PFS over VRD alone even in pts achieving MRD negativity
> Deepened response when using Dara-VTd plus ASCT vs Dara-VTd
> ASCT improves MRD negativity and PFS in pts with high-risk cytogenetics

#mmsm #myeloma

X post image

14 May 2022

#COMy22 | @nagler_EBMT argued in favour of ASCT as frontline;

> Sustained MRD negativity with ASCT
> ASCT has demonstrated improved PFS, OS, and CR over conventional CT
> Improvement in ORR and PFS was observed in era of novel therapies
#mmsm #myeloma

X post image

14 May 2022

CONGRESS | #COMy22 | Pros continued..

> Data shows deepened responses with Dara-RVd + ASCT vs RVd + ASCT
> Promising results for Isatuximab-RVd without ASCT vs Isa-RVd with ASCT

X post image

14 May 2022

CONGRESS | #COMy22 | Pros continued...

> Increased risk with high-dose melphalan + ASCT for developing AML/MDS
> High dose melphalan increases mutational burden in MM cells at relapse

#mmsm #myeloma

X post image

14 May 2022

#COMy22 | Paul Richardson argued the pros;

> Mutational burden is magnified by high dose melphalan
> Positive effect of ASCT is variable
> Impact of immune microenvironment which is subject to big change with transplant
> ASCT does not have a clear advantage for OS

#mmsm

X post image

14 May 2022

CONGRESS | #COMy22 | Paul Richardson, @Danafarber, and @nagler_EBMT, @SHEBA_, discussed the pros and cons of immune therapies replacing ASCT frontline

#mmsm #myeloma @COMyCongress

X post image

14 May 2022

📰 It's day 3 of #COMy22!

The MM Hub will be covering:
Session 11: Hot debates
Session 13: Immune therapy in relapsed/refractory #myeloma

Follow us (@mm_hub) for the latest updates from today! 🗞️

@COMyCongress #mmsm

X post image

13 May 2022

CONGRESS | #COMy22 | Olivier Decaux and colleagues presented their posters on the EMMY study, with real-life use of lenalidomide-dexamethasone or pomalidomide in MM.

X post image

13 May 2022

CONGRESS | #COMy22 | Jackson presented data on predicting who is at high risk of developing infection and therefore who should be targeted with anti-biotic prophylaxis, and presented other potential infection threats

#mmsm #myeloma

X post image

13 May 2022

CONGRESS | #COMy22 | The TEAMM study looked at the benefit of antibiotic prophylaxis in early myeloma treatment, which reduced the no. of febrile events and deaths compared with placebo within 12 weeks

#mmsm #myeloma

X post image

13 May 2022

CONGRESS | #COMy22 | @profghjackson, @UniofNewcastle, highlighted that pneumonia and infection are major causes for early mortality in #myeloma, and risk of infection is greatest in first 2-3 months of treatment, while severe infections affect OS further

#mmsm @COMyCongress

X post image

13 May 2022

#COMy22 Finally, Ludwig described methods to improve Ab and T cell response in pts with #myeloma, including additional vaccine doses and more immunogenic vaccines

#COVID19 #SARSCoV2

X post image

13 May 2022

#COMy22 A third vaccine dose increased the neutralizing activity of Abs in patients who develop anti S Abs but the neutralizing capacity against the omicron variant was much lower

#mmsm #myeloma #COVID19 #SARSCoV2

X post image

13 May 2022

#COMy22 PIs, immunomodulators, CAR-T therapy are associated with increased risk of breakthrough infection and risk for infection was affected by the type of vaccine used
#mmsm #COVID19 #myeloma #SARSCoV2

X post image

13 May 2022

#COMy22 Ludwig described median anti S1 Ab response with different #myeloma treatments following two vaccine doses, and identified risk factors for poor response including response status, lymphopenia ≥ grade 3, BCMA-targeted treatment, and use of anti-CD38 therapy #mmsm

X post image

13 May 2022

#COMy22 | Heinz Ludwig described post exposure prophylaxis options in pts with high risk for severe #COVID19 disease, highlighting the antiviral drug Nirmatrelvir/ritonavir

#mmsm #SARSCoV2 #myeloma

X post image

13 May 2022

CONGRESS | #COMy22 | Heinz Ludwig, Wilhelminen Cancer Research Institute, discussed #COVID19 infection in patients with #myeloma, first highlighting persistence of the virus with ongoing treatment

#mmsm #SARSCoV2

X post image

13 May 2022

CONGRESS | #COMy22 | Yong described how to take into account the patients perspective, highlighting the importance of a multi-disciplinary team for support and managing expectations early in treatment

X post image

13 May 2022

#COMy22 | Quality of life becomes critical as treatment-free intervals are shortened, and choice of regimen influence HR-QoL, with most toxicities increasing in frequency with increased lines of therapy, and the % of pts without any events decreasing

#mmsm #myeloma

X post image

13 May 2022

#COMy22 | Yong outlined important themes related to a patients quality of life focusing on emotional status, activity and participation, and support factors which are influenced by pain, fatigue and physical functioning

#mmsm #myeloma

X post image

13 May 2022

CONGRESS | #COMy22 | Yong described the importance of language and narrative to improve patient and physician understanding and limit the influence of external factors such as stories from internet

#mmsm

X post image

13 May 2022

CONGRESS | #COMy22 | Kwee Yong, @uclh, provided an overview of the emotional wellbeing and health related QoL from the patient perspective with MM treatment

#mmsm #myeloma

X post image

13 May 2022

RT @sci_ed_support: Have you been keeping an eye on the live Twitter updates?

@MM_Hub is covering some exciting topics from #COMy22 all th…

X post image

13 May 2022

#COMy22 | Facon detailed phase II trials on NDMM not eligible for allo-HSCT including improved PFS with inclusion of dara in Rd and VMP containing regimens, and detailed the treatment landscape that combines dara with Rd and VMP, and other novel agents such as new IMids
#mmsm

X post image

13 May 2022

#COMy22 | Daratumumab made a difference for PFS also in frail patients, with more adverse events in this patient subgroup as expected
#mmsm

X post image

13 May 2022

#COMy22 | In terms of safety, increased Grade 3-4 neutropenia was reported with D-Rd vs Rd, and a small increase in infections was reported with D-VMP and D-Rd compared with either Rd or VMP alone, plus an increase in pneumonia

#mmsm #myeloma

X post image

13 May 2022

CONGRESS | #COMy22 | Thierry Facon, @CHU_Lille, described study data for standard of care therapy in NDMM

👉RVd lite for older pts produced an ORR of 86%

👉Daratumumab produced a significant benefit for PFS and OS (in both d-Rd and d-VMP combinations)

#mmsm @COMyCongress

X post image

13 May 2022

#COMy22 | Larocca finally outlined adjusted treatment strategies for unfit and frail patients

#mmsm

X post image

13 May 2022

#COMy22 | Larocca described the limitations of the frailty scores, and suggested the potential of frailty biomarkers such as sarcopenia with age associated decline in skeletal muscle mass assessed by CT that was predictive of treatment discontinuation and OS

#mmsm #myeloma

X post image

13 May 2022

#COMy22 | Larocca presented data demonstrating improved discriminative power with revised frailty scoring systems and accurate prediction of overall survival
#mmsm

X post image

13 May 2022

#COMy22 | Alessandra Larocca, @FGIMEMA, detailed assessment of frailty in pts with #myeloma, highlighting firstly that geriatric assessment is an efficient method to identify patients who can benefit from more curative approaches, and is different from performance status

#mmsm

X post image

13 May 2022

📰 It's day 2 of #COMy22!

The MM Hub will be covering:
Session 7: Treatment of non-transplant eligible patients
Session 8: Management of special clinical situations

Follow us on twitter (@mm_hub) for the latest updates from today! 🗞️

@COMyCongress #mmsm

X post image

12 May 2022

CONGRESS | #COMy22 | Mohamed Amine Bekadja, et al presented their poster on the safety and efficacy of autologous transplant with non-cryopreserved PBSC. The data is taken from pts with myeloma or lymphoma, treated in Algeria between 2009-2019.

X post image

12 May 2022

RT @sci_ed_support: SES is delighted to be attending #COMy22 virtually and in person this year. Partnerships Manager Geoff Jones will be in…

X post image

12 May 2022

CONGRESS | #COMy22 | @Nbahlis described how novel CELMoDs can overcome this resistance through higher affinity for CRBN and potent immune modulation of T and NK cells,

X post image

12 May 2022

CONGRESS | #COMy22 | @Nbahlis, @Ucalgary, discussed mechanisms of resistance to IMiDs, including CRBN gene mutations, splicing of CRBN exon 10, mutations in the COP9 signalosome complex, transcriptional plasticity, and MEK/ERK, NF-kB pathway activation

#mmsm

X post image

12 May 2022

#COMy22 Van de Donk discussed the challenges in defining anti-CD38 resistance: due to mAb mechanisms of action, even when MM cells show resistance to CD38-targeting, its effect on the immune system might still achieve disease control. More data in larger cohorts is needed #mmsm

X post image

12 May 2022

CONGRESS | #COMy22 | van de Donk also outlined resistance to bispecific antibodies, focusing on tumor related factors, the MM microenvironment, and T cell specific characteristics

X post image

12 May 2022

CONGRESS | #COMy22 | Niels van de Donk,
@amsterdamumc, discussed resistance mechanisms to anti-CD38 mAbs such daratumumab, highlighting data on upregulation of CD59 expression

#mmsm #myeloma @COMyCongress

X post image

12 May 2022

CONGRESS | #COMy22 | Paola Neri described resistance to BCMA targeting CAR-T therapy, highlighting T-cell characteristics such as loss of CD28 expression and high expression of CD57 indicating the persistence of exhausted T-cells, and loss of BCMA

#mmsm #myeloma

X post image

12 May 2022

CONGRESS | #COMy22 | Marc Raab,
@UniHeidelberg, describes mechanisms of resistance to proteasome inhibitors, highlighting mutations and hypermethylation of PSMD5, an inhibitor of proteasome assembly

#mmsm #myeloma @COMyCongress

X post image

12 May 2022

CONGRESS | #COMy22 | Corre described the importance of alternative splicing isoforms, long intergenic non coding RNAs, some histone modifiers, & studying at a single cell level owing to intra tumor transcriptional heterogeneity #mmsm

X post image

12 May 2022

#COMy22 | Jill Corre, University of Toulouse, discussed the role of the transcriptome in diagnosing risk in multiple #myeloma, highlighting the importance of genes mapped to chromosome 1 for adverse outcomes, and it's limitations for identifying high-risk
#mmsm @COMyCongress

X post image

12 May 2022

CONGRESS | #COMy22 | Hervé Avet-Loiseau, @crctoncopole, described the genetic risk classification of multiple #myeloma, focusing on the optimal definition of high risk using cytogenetic abnormalities

#mmsm @COMyCongress

X post image

12 May 2022

CONGRESS | #COMy22 | @DrRakeshPopat discussed future patient management strategies, including the ocular surface disease index questionnaire, which is a powerful indicator of severe keratopathy

X post image

12 May 2022

#COMy22 | @DrRakeshPopat described the impact of adverse visual acuity events, with 23% of pts from the DREAMM-2 study reporting that they stopped driving, but this was reversible upon treatment interruption. Popat also discussed the impact on reading, which again was reversible

X post image

12 May 2022

CONGRESS | #COMy22 | @DrRakeshPopat outlined the practical management of keratopathy in patients treated with bela, including treatment interruptions from ≥ grade 2 and dose modifications
#mmsm

X post image

12 May 2022

CONGRESS | #COMy22 | @DrRakeshPopat described the practical management of adverse events in patients, focusing on keratopathy associated with belantamab mafodotin
#mmsm

X post image

12 May 2022

CONGRESS | #COMy22 | Truder finished by outlining phase I results of novel BCMA targeting ADCs
#mmsm

X post image

12 May 2022

CONGRESS | #COMy22 | Truder outlined the DREAMM-6 study investigating bela + Vd which produced a median duration of response that was not reached, and the algonquin study, investigating Bela + pomalidomide, showing high PFS and an ORR of 89%
#mmsm

X post image

12 May 2022

CONGRESS | #COMy22 | Truder described the multiple MoA of @US_FDA approved belantamab mafodotin, which is used for r/r MM, based on results of the DREAMM-2 study showing an ORR of 32% that was comparable in both high and standard risk pts
#mmsm

X post image

12 May 2022

CONGRESS | #COMy22 | Suzanne Truder described clinical results of ADCs in r/r multiple #myeloma, firstly highlighting the improvement in ORR with BCMA targeting ADCs
#mmsm

X post image

12 May 2022

CONGRESS | #COMy22 | Mainer described the immune effects of ADCs, including direct cytotoxic effects and immunogenic cell death
#mmsm

X post image

12 May 2022

CONGRESS | #COMy22 | Salomon Mainer described the mechanism of action of ADCs and the challenges of ADC design
#mmsm

X post image

12 May 2022

CONGRESS | #COMy22 | @Mohty_EBMT chaired an insightful symposium on antibody drug conjugates in r/r multiple #myeloma, with discussion from Salomon Mainer, Suzanne Trudel, and @DrRakeshPopat

#mmsm @COMyCongress

X post image

12 May 2022

It's day 1 of #COMy22!

The @MM_Hub will be covering:
Session 1: How to assess disease risk
Session 2: Mechanisms of resistance in #myeloma

@COMyCongress #mmsm

X post image

10 May 2022

We will be covering the 8th World Congress on Controversies in Multiple Myeloma @COMyCongress.
The congress chairs for the event are @Mohty_EBMT @nagler_EBMT and Thierry Facon! Keep an eye on our socials for live coverage from our virtual and in-person attendance!#COMy22 #mmsm

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

COMy 2022 Controversies in Multiple Myeloma

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox